PL3052476T3 - Podstawione nikotynoimidowe inhibitory btk oraz sposób ich wytwarzania i zastosowanie w leczeniu raka, stanu zapalnego i chorób automunnologicznych - Google Patents

Podstawione nikotynoimidowe inhibitory btk oraz sposób ich wytwarzania i zastosowanie w leczeniu raka, stanu zapalnego i chorób automunnologicznych

Info

Publication number
PL3052476T3
PL3052476T3 PL14848083T PL14848083T PL3052476T3 PL 3052476 T3 PL3052476 T3 PL 3052476T3 PL 14848083 T PL14848083 T PL 14848083T PL 14848083 T PL14848083 T PL 14848083T PL 3052476 T3 PL3052476 T3 PL 3052476T3
Authority
PL
Poland
Prior art keywords
nicotinimide
btk
inflammation
inhibitors
cancer
Prior art date
Application number
PL14848083T
Other languages
English (en)
Inventor
Xiangyang Chen
Yingxiang GAO
Chong LIU
Haihong Ni
Mark Mulvihill
Original Assignee
Guangzhou Innocare Pharma Tech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Innocare Pharma Tech Co., Ltd. filed Critical Guangzhou Innocare Pharma Tech Co., Ltd.
Publication of PL3052476T3 publication Critical patent/PL3052476T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL14848083T 2013-09-30 2014-09-29 Podstawione nikotynoimidowe inhibitory btk oraz sposób ich wytwarzania i zastosowanie w leczeniu raka, stanu zapalnego i chorób automunnologicznych PL3052476T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361884958P 2013-09-30 2013-09-30
CN201310485048 2013-10-16
PCT/US2014/058084 WO2015048662A2 (en) 2013-09-30 2014-09-29 Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
EP14848083.3A EP3052476B1 (en) 2013-09-30 2014-09-29 Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

Publications (1)

Publication Number Publication Date
PL3052476T3 true PL3052476T3 (pl) 2021-01-11

Family

ID=52497918

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14848083T PL3052476T3 (pl) 2013-09-30 2014-09-29 Podstawione nikotynoimidowe inhibitory btk oraz sposób ich wytwarzania i zastosowanie w leczeniu raka, stanu zapalnego i chorób automunnologicznych

Country Status (16)

Country Link
US (6) US9951056B2 (pl)
EP (1) EP3052476B1 (pl)
JP (1) JP6615752B2 (pl)
KR (1) KR102272792B1 (pl)
CN (1) CN104341388B (pl)
AU (1) AU2014324595B2 (pl)
CA (1) CA2925624C (pl)
CY (1) CY1123388T1 (pl)
MX (1) MX2016004030A (pl)
PL (1) PL3052476T3 (pl)
RS (1) RS60934B1 (pl)
RU (1) RU2677884C2 (pl)
SG (1) SG11201602070TA (pl)
SI (1) SI3052476T1 (pl)
SM (1) SMT202000549T1 (pl)
WO (1) WO2015048662A2 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3052476T3 (pl) * 2013-09-30 2021-01-11 Guangzhou Innocare Pharma Tech Co., Ltd. Podstawione nikotynoimidowe inhibitory btk oraz sposób ich wytwarzania i zastosowanie w leczeniu raka, stanu zapalnego i chorób automunnologicznych
EP3060550B1 (en) * 2013-10-21 2019-05-15 Merck Patent GmbH Heteroaryl compounds as btk inhibitors and uses thereof
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CA2967853A1 (en) * 2014-12-11 2016-06-16 Merck Patent Gmbh Assays for btk inhibitors
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
CN114591242B (zh) 2015-12-16 2025-01-07 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
KR102404759B1 (ko) * 2016-05-16 2022-05-31 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. Ｂｔｋ 억제제로서의 5-아미노피라졸 카르복사미드 유도체 및 그것의 제조 방법 및 제약학적 조성물
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107646855B (zh) * 2017-08-02 2020-07-07 浙江工业大学 一种含哌啶噻唑类化合物在制备杀菌剂中的应用及其制备方法
EP3689871B1 (en) * 2017-09-28 2021-09-29 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 4,6,7-trisubstituted 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative and use
JP7273716B2 (ja) * 2017-09-29 2023-05-15 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
KR102717600B1 (ko) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
EP3788033A1 (en) * 2018-05-04 2021-03-10 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
CN117281803A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
CA3111114A1 (en) 2018-09-18 2020-03-26 Beijing Innocare Pharma Tech Co., Ltd. Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide
CN110964016B (zh) 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 氨基降茨烷衍生物及其制备方法与应用
ES2945834T3 (es) 2018-10-05 2023-07-07 Forma Therapeutics Inc Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30)
AU2019376368B2 (en) * 2018-11-06 2025-05-08 Beijing Innocare Pharma Tech Co., Ltd. Amorphous solid dispersion comprising 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide
DK3880675T3 (da) 2018-11-12 2024-12-02 Debiopharm Int Sa Antibiotiske forbindelser, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger indeholdende disse og anvendelser deraf
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3894403A1 (en) * 2018-12-13 2021-10-20 Intervet International B.V. Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide
CN113454066B (zh) * 2019-02-25 2024-02-09 北京诺诚健华医药科技有限公司 制备6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的工艺
EP3851438A4 (en) * 2019-03-18 2021-11-10 Shanghai Haiyan Pharmaceutical Technology Co., Ltd BTK INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPHIC AND APPLICATION OF THE SAME
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113563305B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(n-取代氧基羰基哌啶-4-)基烟酰胺的制备方法
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
CN114085207B (zh) * 2020-10-16 2024-06-25 广州百霆医药科技有限公司 布鲁顿酪氨酸蛋白激酶抑制剂及其应用
CN114957242B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 吡啶并杂环类化合物作为激酶抑制剂的制备及其应用
CN114853752B (zh) * 2021-02-03 2023-08-22 药雅科技(上海)有限公司 Btk抑制剂吡啶并杂环类化合物的制备及其应用
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
US12162870B2 (en) * 2021-06-08 2024-12-10 The Regents Of The University Of California Anticancer compounds
IL309427A (en) * 2021-07-01 2024-02-01 Hangzhou Healzen Therapeutics Co Ltd TYROSINE KINASE AND MUTANT DEGRADER, Broughton's composition and application
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114920844B (zh) * 2022-06-27 2023-12-29 上海润诺生物科技有限公司 一种增强car-t功能的合成纳米抗体及其制备方法和应用
CN115894440B (zh) * 2022-10-27 2024-10-22 都创(重庆)医药科技有限公司 奥布替尼化合物的晶型及其制备方法
CN118063429B (zh) * 2022-11-23 2025-02-25 天津瑞程健达医药科技有限公司 作为btk抑制剂的吡啶酰胺类化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
CN101060842A (zh) 2004-09-21 2007-10-24 葛兰素集团有限公司 化合物
PE20060748A1 (es) * 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
US7589214B2 (en) * 2006-04-11 2009-09-15 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CA3001152A1 (en) * 2007-03-28 2008-10-09 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US8450335B2 (en) * 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
GB0820819D0 (en) * 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
EP2440204B1 (en) * 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
US8846673B2 (en) * 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
BR112013006272A2 (pt) * 2010-09-17 2019-09-24 Purdue Pharma Lp compostos de piridina e seus usos
WO2012158810A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
LT2718270T (lt) * 2011-06-10 2022-08-10 Merck Patent Gmbh Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
CN102827073A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
MX2015001802A (es) * 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
MD20150035A2 (ro) * 2012-11-02 2015-10-31 Pfizer Inc. Inhibitori de tirozinkinaza Bruton
BR112015011171A2 (pt) * 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014151620A1 (en) * 2013-03-14 2014-09-25 Boehringer Ingelheim International Gmbh 5-thiazolecarboxamide dervatives and their use as btk inhibitors
EA028756B1 (ru) 2013-04-25 2017-12-29 Бэйджин, Лтд. Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
BR112015032330B1 (pt) 2013-06-26 2019-01-22 Abbvie Inc. carboxamidas primárias como inibidores de bkt
PL3052476T3 (pl) * 2013-09-30 2021-01-11 Guangzhou Innocare Pharma Tech Co., Ltd. Podstawione nikotynoimidowe inhibitory btk oraz sposób ich wytwarzania i zastosowanie w leczeniu raka, stanu zapalnego i chorób automunnologicznych
EP3060550B1 (en) * 2013-10-21 2019-05-15 Merck Patent GmbH Heteroaryl compounds as btk inhibitors and uses thereof

Also Published As

Publication number Publication date
KR102272792B1 (ko) 2021-07-05
US10301297B2 (en) 2019-05-28
US20190276446A1 (en) 2019-09-12
KR20160058188A (ko) 2016-05-24
RU2677884C2 (ru) 2019-01-22
SI3052476T1 (sl) 2020-12-31
JP2016531893A (ja) 2016-10-13
EP3052476B1 (en) 2020-07-15
RU2016115803A (ru) 2017-11-09
US11345695B2 (en) 2022-05-31
US20240101545A1 (en) 2024-03-28
SG11201602070TA (en) 2016-04-28
US20180222897A1 (en) 2018-08-09
US11840513B2 (en) 2023-12-12
US20250059176A1 (en) 2025-02-20
JP6615752B2 (ja) 2019-12-04
CY1123388T1 (el) 2021-12-31
RS60934B1 (sr) 2020-11-30
AU2014324595A1 (en) 2016-04-07
SMT202000549T1 (it) 2020-11-10
US20160237075A1 (en) 2016-08-18
CA2925624A1 (en) 2015-04-02
US12162873B2 (en) 2024-12-10
US9951056B2 (en) 2018-04-24
HK1207063A1 (en) 2016-01-22
RU2016115803A3 (pl) 2018-05-16
MX2016004030A (es) 2016-10-26
CA2925624C (en) 2021-06-15
AU2014324595B2 (en) 2018-12-20
WO2015048662A3 (en) 2015-05-07
CN104341388A (zh) 2015-02-11
WO2015048662A2 (en) 2015-04-02
US20220298153A1 (en) 2022-09-22
CN104341388B (zh) 2017-03-22
EP3052476A4 (en) 2017-03-29
EP3052476A2 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
SG11201602070TA (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB201320729D0 (en) Therapeutic compounds and their use
ZA201505735B (en) Cancer drug and uses
SG11201509259RA (en) Bispecific constructs and their use in the treatment of various diseases
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
IL242483B (en) Preparations containing omomyc and their use for cancer treatment
IL239904A0 (en) Inhibitory oligonucleotides and their use in therapy
GB201311361D0 (en) Compounds and their therapeutic use
IL245738A0 (en) Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases
IL244901A0 (en) Derivatives of aminotetralin and aminoindan, pharmaceutical compositions containing them and their use in therapy
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
GB201308736D0 (en) Compounds and their therapeutic use
EP2969008A4 (en) MEDICATION FOR THE TREATMENT OF CANCER, CARDIOVASCULAR DISEASES AND INFLAMMATION
IL244435A0 (en) Fidotimide for use in the treatment of diseases associated with inflammation
GB201308753D0 (en) Compounds and their use in therapy
HUE050771T2 (hu) BTK szubsztituált nikotinimid inhibitorai és készítményeik és alkalmazásuk rák, gyulladás és autoimmun betegség kezelésében
GB201308217D0 (en) Compounds and their use in therapy
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
GB201312129D0 (en) Drug combination and its use in therapy
GB201312131D0 (en) Drug combination and its use in therapy
GB201312128D0 (en) Drug combination and its use in therapy
TH1401007652A (th) อะมิโนไตรอะโซโลไพริดีนสำหรับการใช้ในการรักษาการอักเสบ และองค์ประกอบทางเภสัชกรรมของมัน